Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about KDM6A: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
Lysine Specific Demethylase 6A (UTX) - histone demethylase regulating gene expression in neurodevelopment and neurodegeneration
No AI portrait yet
| Gene Symbol | KDM6A |
| Aliases | Lysine Specific Demethylase 6A (UTX), Lysine Specific Demethylase 6A (UTX |
| Protein Type | Epigenetic Regulator |
| Target Class | Epigenetic Regulator |
| Function | Small molecule inhibition of histone demethylase activity |
| Mechanism of Action | Small molecule inhibition of histone demethylase activity |
| Druggability | Low (0.35) |
| Clinical Stage | Phase I |
| Molecular Weight | 160 kDa |
| Amino Acids | 401 aa |
| Exons | 29 |
| Pathways | Epigenetic |
| UniProt ID | A0A087X0R0 |
| GeneCards | KDM6A |
| Human Protein Atlas | KDM6A |
| Associated Diseases | cancer, inflammation, neurodegeneration, OXIDATIVE STRESS, SYNAPTIC PLASTICITY |
| Known Drugs/Compounds | GSK-J4 |
| Interactions | AND, App, ASCL1, ATM, BRCA2, BRG1 |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | KDM6A-Mediated H3K27me3 Rejuvenation |
| KG Connections | 151 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |
Knowledge base pages for this entity
graph TD
KDM6A["KDM6A"]
neurodegeneration{"neurodegeneration"}
KDM6A -->|"implicated in"| neurodegeneration
KDM6A -->|"associated with"| neurodegeneration
SIRT6["SIRT6"]
KDM6A -->|"co discussed"| SIRT6
DNMT1["DNMT1"]
KDM6A -->|"co discussed"| DNMT1
FOXO3["FOXO3"]
KDM6A -->|"co discussed"| FOXO3
h_881362dc["h-881362dc"]
h_881362dc -->|"therapeutic target"| KDM6A
h_881362dc -->|"targets"| KDM6A
HDAC3["HDAC3"]
HDAC3 -->|"co discussed"| KDM6A
TET2["TET2"]
TET2 -->|"co discussed"| KDM6A
style KDM6A fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0| Target | Relation | Type | Str |
|---|---|---|---|
| H3K27me3 | demethylates | histone_mark | 0.80 |
| MMP3 | inhibits | gene | 0.70 |
| CREB | interacts_with | gene | 0.70 |
| Lung Cancer | regulates | disease | 0.65 |
| Cancer | regulates | disease | 0.65 |
| Prostate Cancer | treats | disease | 0.65 |
| Cancer | inhibits | disease | 0.65 |
| Aging | treats | disease | 0.65 |
| Carcinoma | therapeutic_target | disease | 0.65 |
| Cancer | therapeutic_target | disease | 0.65 |
| Als | therapeutic_target | disease | 0.65 |
| Carcinoma | activates | disease | 0.65 |
| Tumor | inhibits | disease | 0.65 |
| Als | activates | disease | 0.65 |
| Glioblastoma | activates | disease | 0.65 |
| Als | regulates | disease | 0.65 |
| Tumor | activates | disease | 0.65 |
| Cancer | activates | disease | 0.65 |
| Spinal Cord Injury | inhibits | disease | 0.65 |
| T Cell | regulates | cell_type | 0.60 |
| App | inhibits | protein | 0.60 |
| CANCER | activates | gene | 0.60 |
| GLIOBLASTOMA | activates | gene | 0.60 |
| Mtor | activates | pathway | 0.60 |
| Pi3K/Akt | activates | pathway | 0.60 |
| Histone Modification | activates | pathway | 0.60 |
| Glycolysis | activates | pathway | 0.60 |
| GLUD1 | regulates | gene | 0.60 |
| AKT | regulates | gene | 0.60 |
| MTOR | activates | gene | 0.60 |
| NEUROD1 | activates | gene | 0.60 |
| MLCK | inhibits | gene | 0.60 |
| PI3K | activates | gene | 0.60 |
| EGFR | regulates | gene | 0.60 |
| GBM | activates | gene | 0.60 |
| CANCER | regulates | gene | 0.60 |
| GENES | activates | gene | 0.60 |
| Epigenetic | regulates | pathway | 0.60 |
| macrophages | inhibits | cell_type | 0.60 |
| SYNAPTIC PLASTICITY | implicated_in | phenotype | 0.60 |
| OXIDATIVE STRESS | increases_risk | phenotype | 0.60 |
| FGFR3 | activates | gene | 0.60 |
| EZH2 | inhibits | gene | 0.60 |
| Nk Cell | regulates | cell_type | 0.60 |
| KMT2D | activates | gene | 0.60 |
| FGFR3 | therapeutic_target | gene | 0.60 |
| spinal cord | expressed_in | brain_region | 0.60 |
| SUCCINATE | produces | phenotype | 0.60 |
| Adaptive Immunity | treats | pathway | 0.60 |
| Immunotherapy | treats | pathway | 0.60 |
| Source | Relation | Type | Str |
|---|---|---|---|
| h-881362dc | targets | hypothesis | 0.90 |
| ASCL1 | activates | gene | 0.60 |
| TP53 | therapeutic_target | gene | 0.60 |
| KMT2D | associated_with | gene | 0.60 |
| RB1 | therapeutic_target | gene | 0.60 |
| PIK3CA | therapeutic_target | gene | 0.60 |
| PTEN | inhibits | gene | 0.60 |
| CANCER | activates | gene | 0.60 |
| EZH2 | activates | gene | 0.60 |
| GENES | associated_with | gene | 0.60 |
| CANCER | therapeutic_target | gene | 0.60 |
| TP53 | activates | gene | 0.60 |
| OVERVIEW | activates | gene | 0.60 |
| RB1 | activates | gene | 0.60 |
| PIK3CA | activates | gene | 0.60 |
| CD38 | regulates | gene | 0.60 |
| AND | associated_with | gene | 0.60 |
| HK2 | activates | gene | 0.60 |
| PDPK1 | activates | gene | 0.60 |
| CSF | stabilizes | phenotype | 0.60 |
| C1Q | activates | gene | 0.55 |
| DNA | activates | gene | 0.55 |
| CREB | activates | gene | 0.55 |
| BRG1 | activates | gene | 0.55 |
| CBP | activates | gene | 0.55 |
| KDM1A | activates | gene | 0.55 |
| ALZHEIMER'S DISEASE | associated_with | disease | 0.50 |
| ALZHEIMER | associated_with | disease | 0.50 |
| STROKE | associated_with | disease | 0.50 |
| CANCER | associated_with | disease | 0.50 |
| HDAC | debate_co_mention | gene | 0.45 |
| CLOCK | debate_co_mention | gene | 0.45 |
| DNMT1 | debate_co_mention | gene | 0.45 |
| FOXO3 | debate_co_mention | gene | 0.45 |
| HDAC3 | debate_co_mention | gene | 0.45 |
| SPINAL CORD INJURY | associated_with | disease | 0.45 |
| SPINAL CORD | associated_with | brain_region | 0.45 |
| DNMT1 | co_associated_with | gene | 0.40 |
| DNMT1 | co_discussed | gene | 0.40 |
| SIRT6 | co_discussed | gene | 0.40 |
| FOXO3 | co_discussed | gene | 0.40 |
| HDAC3 | co_discussed | gene | 0.40 |
| TET2 | co_discussed | gene | 0.40 |
| FOXO3 | co_associated_with | gene | 0.40 |
| HDAC3 | co_associated_with | gene | 0.40 |
| HDAC | co_discussed | gene | 0.40 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| KDM6A-Mediated H3K27me3 Rejuvenation | 0.653 | neurodegeneration | Epigenetic clocks and biological aging i |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 6 hypotheses Top: 0.710
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Proposed experiment from debate on Epigenetic clocks and biological ag | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $450,000 |
| Cognitive Reserve Mechanisms in Alzheimer's Disease — Molecular Basis | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| DNA Damage Repair Deficiency Validation Study in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Epigenetic Clocks in Neurodegeneration — Causal Drivers or Passive Mar | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Epigenetic Dysregulation in Huntington's Disease — Therapeutic Targeti | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,000,000 |
| LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Never Develo | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a sp [PMID:22729224] | ["Rivi\u00e8re J", "Mirzaa G", "O'Roak B | Nature Genetics | 2012 | 748 |
| High-Resolution Differentiation of Enteric Bacteria in Premature Infant Fecal Mi [PMID:33593974] | Graf J, Ledala N, Caimano MJ, Jackson E, | mBio | 2021 | 1 |
| Development of a deep learning-based software for calculating cleansing score in [PMID:33627678] | Nam JH, Hwang Y, Oh DJ, Park J, Kim KB, | Sci Rep | 2021 | 1 |
| Bacterial siderophores in community and host interactions. [PMID:31748738] | Kramer J, Özkaya Ö, Kümmerli R | Nat Rev Microbiol | 2020 | 1 |
| SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. [PMID:33398264] | Turner JS, Kim W, Kalaidina E, Goss CW, | Res Sq | 2020 | 1 |
| ApoE-associated modulation of neuroprotection from Aβ-mediated neurodegeneration [PMID:30683808] | Griffin EF, Scopel SE, Stephen CA, Holzh | Dis Model Mech | 2019 | 1 |
| Endodermal Maternal Transcription Factors Establish Super-Enhancers during Zygot [PMID:31167141] | Paraiso KD, Blitz IL, Coley M, Cheung J, | Cell Rep | 2019 | 1 |
| Modification of ASC1 by UFM1 is crucial for ERα transactivation and breast cance [PMID:25219498] | Yoo HM, Kang SH, Kim JY, Lee JE, Seong M | Mol Cell | 2014 | 1 |
| Foxh1 is a locus-specific PRC2 recruiter governing germ layer silencing. [PMID:41040321] | ["Cho J", "Hendrickson C", "Mar N", "Bli | bioRxiv : the preprint server | 2025 | 0 |
| Epigenetic regulation of bladder cancer in the context of aging. [PMID:40918525] | ["Liu X", "Ding G", "Liu Y", "Yan X", "Z | Frontiers in pharmacology | 2025 | 0 |
| Loss of Kmt2c or Kmt2d drives brain metastasis via KDM6A-dependent upregulation [PMID:38926506] | Seehawer M, Li Z, Nishida J, Foidart P, | Nature cell biology | 2024 | 0 |
| Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multipl [PMID:38355622] | Liu J, Xing L, Li J, Wen K, Liu N, Liu Y | Nature communications | 2024 | 0 |
| Wnt-deficient and hypoxic environment orchestrates squamous reprogramming of hum [PMID:39232216] | Tamagawa H, Fujii M, Togasaki K, Seino T | Nature cell biology | 2024 | 0 |
| KDM6A epigenetically regulates subtype plasticity in small cell lung cancer. [PMID:37591951] | Duplaquet L, Li Y, Booker MA, Xie Y, Ols | Nature cell biology | 2023 | 0 |
| H3K36 dimethylation shapes the epigenetic interaction landscape by directing rep [PMID:35396277] | ["Chen H", "Hu B", "Horth C", "Bareke E" | Genome research | 2022 | 0 |
| An intramembrane chaperone complex facilitates membrane protein biogenesis. [PMID:32814900] | ["Chitwood PJ", "Hegde RS"] | Nature | 2020 | 0 |
| In vitro anti-HIV-1 activity of the bioactive compound extracted and purified fr [PMID:31434919] | ["Sanniyasi E", "Venkatasubramanian G", | Scientific reports | 2019 | 0 |
| Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation an [PMID:31747604] | Yamagishi M, Hori M, Fujikawa D, Ohsugi | Cell reports | 2019 | 0 |
| Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma. [PMID:31409811] | ["Kim T", "Woo S", "Lee W", "Oh E", "You | Scientific reports | 2019 | 0 |
| Opportunities and obstacles for deep learning in biology and medicine. [PMID:29618526] | ["Ching T", "Himmelstein D", "Beaulieu-J | Journal of the Royal Society, | 2018 | 0 |
Multi-agent debates referencing this entity
Hypotheses and analyses mentioning KDM6A in their description or question text
No additional research found